ArticleThe mental health clinician2025
Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination.
Article in The mental health clinician, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Opioid overdose deaths continue to rise despite available safe and efficacious treatments for opioid use disorder, such as buprenorphine. Whereas provider-level access to buprenorphine has improved, community pharmacy-level barriers remain, related to patient stigma and regulatory concerns. Education programs improve pharmacist comfort in dispensing naloxone. Because naloxone education improves naloxone dispensing comfort, buprenorphine education may improve stocking and dispensing of buprenorphine. Methods: An evidence-based, best practices continuing education (CE) program about buprenorphine, including regulatory agency truths, was delivered to an audience of community pharmacists. To develop this CE program, interviews were conducted with key regulatory stakeholders including the Drug Enforcement Agency, board of pharmacy, and pharmaceutical distributors. Community pharmacist attendees completed a postsession anonymous survey on their knowledge about and comfort level toward buprenorphine following this CE program. Represented community pharmacies were contacted by phone approximately 1 month following this session to determine the immediate availability of buprenorphine and naloxone products. Results: At least 75% of pharmacists reported feeling knowledgeable and comfortable about buprenorphine and its related regulations following an evidence-based CE program though buprenorphine was immediately available in only 25% of represented community pharmacies when contacted 1 month following the educational session. Discussion: There are additional needs outside of pharmacist education to support consistent and timely buprenorphine access. Policy adjustments and board of pharmacy support may assist in improving timely and consistent buprenorphine access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.